Several other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Trevena from a buy rating to a hold rating and set a $2.00 price objective on the stock. in a research note on Saturday, January 20th. HC Wainwright lifted their price objective on shares of Trevena to $7.00 and gave the stock a buy rating in a research note on Thursday, March 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $7.06.
Trevena (NASDAQ TRVN) opened at $1.92 on Monday. Trevena has a one year low of $1.34 and a one year high of $3.98. The firm has a market cap of $119.62, a P/E ratio of -1.57 and a beta of -0.61. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.71 and a current ratio of 3.71.
Institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in Trevena by 37.8% in the third quarter. Dimensional Fund Advisors LP now owns 980,440 shares of the biopharmaceutical company’s stock valued at $2,500,000 after buying an additional 268,825 shares in the last quarter. Vanguard Group Inc. lifted its stake in Trevena by 15.0% in the second quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock valued at $4,191,000 after buying an additional 238,089 shares in the last quarter. Northern Trust Corp lifted its stake in Trevena by 15.8% in the second quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock valued at $1,318,000 after buying an additional 77,934 shares in the last quarter. Bourgeon Capital Management LLC lifted its stake in Trevena by 59.3% in the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 51,300 shares in the last quarter. Finally, Northpointe Capital LLC lifted its stake in Trevena by 38.2% in the fourth quarter. Northpointe Capital LLC now owns 1,772,557 shares of the biopharmaceutical company’s stock valued at $2,836,000 after buying an additional 489,532 shares in the last quarter. 52.50% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Oppenheimer Analysts Give Trevena (TRVN) a $5.00 Price Target” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/13/oppenheimer-analysts-give-trevena-trvn-a-5-00-price-target.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.